Biohaven's Troriluzole Study For Generalized Anxiety Disorder (GAD) Misses Primary Endpoint

NEW HAVEN, Conn., Feb. 10, 2020 -- (Healthcare Sales & Marketing Network) -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today reported negative topline results from its Phase 3 clinical trial evaluating troriluzole compared to placebo for t... Biopharmaceuticals Biohaven Pharmaceutical, troriluzole, Generalized Anxiety Disorder
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news